Loading...
Please wait, while we are loading the content...
Similar Documents
Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia
| Content Provider | Scilit |
|---|---|
| Author | Sakaguchi, Masahiro Yamaguchi, Hiroki Najima, Yuho Usuki, Kensuke Ueki, Toshimitsu Oh, Iekuni Mori, Sinichiro Kawata, Eri Uoshima, Nobuhiko Kobayashi, Yutaka Kako, Shinichi Tajika, Kenji Gomi, Seiji Shono, Katsuhiro Kayamori, Kensuke Hagihara, Masao Kanda, Junya Uchiyama, Hitoji Kuroda, Junya Uchida, Naoyuki Kubota, Yasushi Kimura, Shinya Kurosawa, Saiko Nakajima, Nana Marumo, Atsushi Omori, Ikuko Fujiwara, Yusuke Yui, Shunsuke Wakita, Satoshi Arai, Kunihito Kitano, Tomoaki Kakihana, Kazuhiko Kanda, Yoshinobu Ohashi, Kazuteru Fukuda, Takahiro Inokuchi, Koiti |
| Copyright Year | 2018 |
| Description | In the opinion of the European LeukemiaNet (ELN), nucleophosmin member 1 gene mutation (NPM1 mut)–positive acute myeloid leukemia (AML) with an fms-like kinase 3-internal tandem duplication (FLT3-ITD) allele ratio (AR) <0.5 (low AR) has a favorable prognosis, and allogeneic hematopoietic stem cell transplant (allo-HSCT) in the first complete remission (CR1) period is not actively recommended. We studied 147 patients with FLT3-ITD gene mutation–positive AML, dividing them into those with low AR and those with AR of ≥0.5 (high AR), and examined the prognostic impact according to allo-HSCT in CR1. Although FLT3-ITD AR and NPM1 mut are used in the prognostic stratification, we found that NPM1 mut–positive AML with FLT3-ITD low AR was not associated with favorable outcome (overall survival [OS], 41.3%). Moreover, patients in this group who underwent allo-HSCT in CR1 had a significantly more favorable outcome than those who did not (relapse-free survival [RFS] P = .013; OS P = .003). Multivariate analysis identified allo-HSCT in CR1 as the sole favorable prognostic factor (RFS P < .001; OS P < .001). The present study found that prognosis was unfavorable in NPM1 mut–positive AML with FLT3-ITD low AR when allo-HSCT was not carried out in CR1. |
| Related Links | https://ashpublications.org/bloodadvances/article-pdf/2/20/2744/882300/advances020305.pdf |
| Ending Page | 2754 |
| Page Count | 11 |
| Starting Page | 2744 |
| DOI | 10.1182/bloodadvances.2018020305 |
| Journal | Blood advances |
| Issue Number | 20 |
| Volume Number | 2 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2018-10-23 |
| Access Restriction | Open |
| Subject Keyword | Hematology Multivariate Analysis Survival Hematopoietic Prognosis Prognostic Rfs Npm1 Flt3 Itd Journal: Blood advances (Vol- 131, Issue- 20) |
| Content Type | Text |
| Resource Type | Article |
